EPRX · Eupraxia Pharmaceuticals Inc. · Investor Relations

$7.59 +0.64 (+9.21%)

Market Cap

$459.21M

66.07M

Volume · Oct 20 938.7K Avg daily vol (3M) 635K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-09-16	Morgan Stanley 24th Annual Global Healthcare Conference	Conference
2026-09-14	H.C. Wainwright 28th Annual Global Investment Conference	Conference
2026-09-11	Cantor Global Healthcare Conference	Conference
2026-07-30	Virtual KOL Event to Discuss Upper Endoscopies and EoE Patients - Understanding How EP-104GI Administration Fits Within Clinical Practice	Event
2026-06-03	Jefferies Global Healthcare Conference	Conference
2026-05-04	Virtual Investor Event at Digestive Disease Week 2026	Event
2026-04-21	2026 Bloom Burton & Co. Healthcare Investor Conference	Conference
2026-04-14	Raymond James Biotech Innovation Symposium	Event
2025-10-01	Webinar - Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs	Webcast
2025-09-09	H.C. Wainwright 27th Annual Global Investment Conference	Conference
2025-09-05	Cantor Global Healthcare Conference	Conference
2025-08-13	Canaccord 45th Annual Growth Conference	Conference
2025-05-14	Tribe Public Webinar Presentation and Q&A Event titled, “Hard To Swallow: An Underdiagnosed Condition Rising To Surface (EOE)	Presentation
2025-05-13	Radius Research - Investments is hosting Eupraxia Pharmaceuticals with CEO James Helliwell for a Live Webinar and Q&A	Event

Source: https://www.eupraxiapharma.com/investors/

Key facts CIK 1581178 CUSIP 29842P105 13F (30d) 1 filings 1 filers Visit website Investor relations